Alma Bio Therapeutics
Alma’s pioneering disease-modifying therapy reinstates balance in a dysregulated immune system that lets inflammation run wild.
- Stage Product In Development
- Industry Biotechnology
- Location Lyon, RA, France
- Currency CHF
- Founded November 2013
- Employees 4
Company Summary
Alma brings forward the first ever curative approach for autoimmune and auto inflammatory diseases of complex etiology . Alma’s therapeutic strategy utilizes body molecules that function as natural Physiological Regulators for managing inflammation. This game-changing approach constitutes a significant extension of immune-modulation therapy to an entirely novel field, achieving groundbreaking therapeutic results that are both effective and safe.
Team
-
Dr. Binah BaumFounder and CEO
Dr. Baum is highly skilled in the university industry interface, in the commercialization of biomedical technologies and in the creation and nurturing of early-stage companies and incubator start-ups. She began her professional career at the VC firm of Adler & Co. She served as VP in 2 israeli VCs, as VP BD at Israel's leading incubator, as consultant to incubators, TTOs and bioclusters and for 5 years on the steering committee of CEBR.
-
Prof. Irun R. Cohen MDFounder, Inventor and CSO
Prof. Cohen has been the Mauerberger Professor of Immunology at the Weizmann Institute of Science; Director, European Collaboration on T Cell Vaccination. Director, Robert Koch-Minerva Center for Research in Autoimmune Diseases; Director of NIBN -the National Institute of Biotechnology in the Negev. Awarded the Robert Koch Prize in autoimmunity ,the Teva Founders Prize, the AESKU Prize and a European Federation of Immunological Societies Prize.
-
Raanan MargalitFounder and CTO
Highly experienced in the development and the utilization of animal models in earlystage drug discovery, with special emphasis on autoimmune and inflammatory diseases,cancer,neurodegenerative disorders as well as disease models involving surgical procedures and/or transplantation. Highly experienced in devising unconventional solutions as well as in guiding company management through the early stages of preclinical work through PoP.
-
Dr. Victor de SouzaRegulatory Consultant
Senior advisor providing expertise and consultancy services to the pharmaceutical industry in regulatory affairs, research and development, and quality affairs/ compliance for new chemical or biotech product development, for marketed products and for generic products. Previously headed regulatory affairs at Speedel, Pharma Division, UCB S.A., F. Hoffmann-La Roche Ltd., Basel and Research Co-Director, Clin Pharm - OSU Cancer Center Ohio.
Advisors
-
FIDAL, LyonLawyerUnconfirmedOrial, LyonAccountantUnconfirmed
Previous Investors
-
Self - foundersUnconfirmedWeizmann Institute of ScienceUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.